Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355 (n)(4)

Carl Norden, M.D.		
Committees:	Anti-Infective Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee	
Meeting Dates:	December 14-15, 2006	
I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the overall benefit to risk considerations for the approved product, Ketek (telithromycin), new drug application (NDA) 21-144, manufactured by Sanofi-Aventis with the current indications of acute bacterial exacerbations of chronic bronchitis, acute bacterial sinusitis, and community acquired pneumonia, I am eligible to receive waivers under 18 U.S.C. §208 (b)(3) and 21 U.S.C. §355(n)(4).		
Type of Interest	Nature	Magnitude
Unrelated Consulting	Competing Firm	Less than \$10,000 per year
Stock	Competing Firm	Valued from \$25,001 to \$50,000
I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.		
/s/		11/9/06
Signature of SGE	D	ate